Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TRIPTORELIN PAMOATE

All injection strengths: general benefit

Trelstar LA (3 Month) · PIN 09857200 · 11.25mg/Vial · injection Pd with Sterile Water-vial

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada brand search: not checked yet (expand to check)

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Trelstar LA (3 Month) · DIN 09857200 Manufacturer: Knight Therapeutics Inc.; listing date 2007-01-02 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada brand search: not checked yet (expand to check)
Check this DIN again

Trelstar LA (3 Month): Formulary list price $1038.9700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1038.9700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857200)

Source record
DIN 09857200: Trelstar LA (3 Month) Raw flags: sec3=Y Item: 100000189; group id 188; item number 0343; lccId None; manufacturer id KNT Source form: Inj Pd with Sterile Water-Vial Pk; strength: 11.25mg/Vial Recorded listing: General benefit Source prices (unrounded): $1038.9700; ministry $1038.9700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857200 Health Canada brand search: not checked yet (expand to check)
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857200
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab

CYPROTERONE ACETATE

· 4 products · General benefit · strengths: 50mg · Tab

DAUNORUBICIN

· 1 products · General benefit · strengths: · Inj Pd-20mg Pk

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TRELSTAR (triptorelin for injectable suspension) is indicated for: • The management and relief of chronic pain associated with endometriosis. • The palliative treatment of hormone dependent advanced carcinoma of the prostate gland (stage D2). For the management and relief of chronic pain in endometriosis, experience in women has been limited to women 18 years of age or older treated for 6 months. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): No data are available to Health Canada for the management and relief of chronic pain associated with endometriosis in geriatric patients. The majority of the patients studied in the clinical trials for the palliative treatment of prostate cancer with TRELSTAR were 65 years and older (see 14 Clinical Trials). https://pdf.hres.ca/dpd_pm/00085331.PDF PM date: 2026-07-14 Source product: TRELSTAR; DIN 02240000; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.